Siddhant Yadav1, Siddharth Singh1, W Scott Harmsen2, Jithinraj Edakkanambeth Varayil1, William J Tremaine1, Edward V Loftus3. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN. 2. Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: loftus.edward@mayo.edu.
Abstract
OBJECTIVES: To estimate the overall risk of cancer in a population-based cohort of patients with inflammatory bowel disease (IBD) and how IBD-related medications modify this risk. METHODS: We identified all incident cancers (excluding nonmelanoma skin cancer) after IBD diagnosis in a cohort of 839 patients diagnosed as having IBD from January 1, 1940, through December 31, 2004, in Olmsted County, Minnesota, and followed up for a median 18 years through December 31, 2011 (122 patients taking biologic agents at last follow-up). We calculated standardized incidence ratios (SIRs) with 95% CIs of all cancers and compared cancer risk in patients treated with immunomodulators (IMMs) and biologics with that of patients not exposed to these medications, using an incidence rate ratio (IRR). RESULTS: One hundred nine patients developed 135 cancers. The 10-year cumulative probability of cancer was 3.8%. Patients with Crohn disease (SIR, 1.6; 95% CI, 1.2-2.1) but not ulcerative colitis (SIR, 1.1; 95% CI, 0.8-1.4) had an increased overall risk of cancer compared with the general population. Patients treated with IMMs (relative to IMM-naive patients) had an increased risk of melanoma (IRR, 5.3; 95% CI, 1.1-24.8) (and a numerically higher risk of hematologic malignant tumors [IRR, 4.2; 95% CI, 0.9-19.2]), although this risk returned to baseline on discontinuation of IMM treatment. Patients treated with biologics (relative to biologic-naive patients) had a numerically higher risk of hematologic malignant tumors (IRR, 5.3; 95% CI, 0.7-40.5). There was no significant increase in the risk of gastrointestinal malignancies in patients with IBD compared with the general population. CONCLUSIONS: We observed an increased risk of melanoma in IMM-treated patients with IBD, and this risk returned to baseline after discontinued use of the medications.
OBJECTIVES: To estimate the overall risk of cancer in a population-based cohort of patients with inflammatory bowel disease (IBD) and how IBD-related medications modify this risk. METHODS: We identified all incident cancers (excluding nonmelanoma skin cancer) after IBD diagnosis in a cohort of 839 patients diagnosed as having IBD from January 1, 1940, through December 31, 2004, in Olmsted County, Minnesota, and followed up for a median 18 years through December 31, 2011 (122 patients taking biologic agents at last follow-up). We calculated standardized incidence ratios (SIRs) with 95% CIs of all cancers and compared cancer risk in patients treated with immunomodulators (IMMs) and biologics with that of patients not exposed to these medications, using an incidence rate ratio (IRR). RESULTS: One hundred nine patients developed 135 cancers. The 10-year cumulative probability of cancer was 3.8%. Patients with Crohn disease (SIR, 1.6; 95% CI, 1.2-2.1) but not ulcerative colitis (SIR, 1.1; 95% CI, 0.8-1.4) had an increased overall risk of cancer compared with the general population. Patients treated with IMMs (relative to IMM-naive patients) had an increased risk of melanoma (IRR, 5.3; 95% CI, 1.1-24.8) (and a numerically higher risk of hematologic malignant tumors [IRR, 4.2; 95% CI, 0.9-19.2]), although this risk returned to baseline on discontinuation of IMM treatment. Patients treated with biologics (relative to biologic-naive patients) had a numerically higher risk of hematologic malignant tumors (IRR, 5.3; 95% CI, 0.7-40.5). There was no significant increase in the risk of gastrointestinal malignancies in patients with IBD compared with the general population. CONCLUSIONS: We observed an increased risk of melanoma in IMM-treated patients with IBD, and this risk returned to baseline after discontinued use of the medications.
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Kevin Haynes; Timothy Beukelman; Jeffrey R Curtis; Craig Newcomb; Lisa J Herrinton; David J Graham; Daniel H Solomon; Marie R Griffin; Lang Chen; Liyan Liu; Kenneth G Saag; James D Lewis Journal: Arthritis Rheum Date: 2013-01
Authors: Mark T Osterman; William J Sandborn; Jean-Frederic Colombel; Anne M Robinson; Winnie Lau; Bidan Huang; Paul F Pollack; Roopal B Thakkar; James D Lewis Journal: Gastroenterology Date: 2013-12-18 Impact factor: 22.682
Authors: Michael D Kappelman; Dora K Farkas; Millie D Long; Rune Erichsen; Robert S Sandler; Henrik T Sørensen; John A Baron Journal: Clin Gastroenterol Hepatol Date: 2013-04-17 Impact factor: 11.382
Authors: Nabeel Khan; Ali M Abbas; Gary R Lichtenstein; Edward V Loftus; Lydia A Bazzano Journal: Gastroenterology Date: 2013-07-25 Impact factor: 22.682
Authors: Siddharth Singh; Sajan Jiv Singh Nagpal; Mohammad H Murad; Siddhant Yadav; Sunanda V Kane; Darrell S Pardi; Jayant A Talwalkar; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2013-05-02 Impact factor: 11.382
Authors: Tine Jess; Erzsébet Horváth-Puhó; Jan Fallingborg; Henrik H Rasmussen; Bent A Jacobsen Journal: Am J Gastroenterol Date: 2013-08-27 Impact factor: 10.864
Authors: Jacob A Burns; Adam B Weiner; William J Catalona; Eric V Li; Edward M Schaeffer; Stephen B Hanauer; Scott Strong; James Burns; Maha H A Hussain; Shilajit D Kundu Journal: Eur Urol Date: 2018-12-04 Impact factor: 20.096
Authors: Tiziana Larussa; Antonio Basile; Caterina Palleria; Chiara Iannelli; Ada Vero; Lidia Giubilei; Caterina De Sarro; Evelina Suraci; Raffaella Marasco; Maria Imeneo; Emilio Russo; Ludovico Abenavoli; Giovambattista De Sarro; Francesco Luzza Journal: Med Pharm Rep Date: 2021-07-29
Authors: Abha G Singh; Cynthia S Crowson; Siddharth Singh; Mark Denis P Davis; Hilal Maradit-Kremers; Eric L Matteson; Vaidehi R Chowdhary Journal: Rheumatology (Oxford) Date: 2016-08-12 Impact factor: 7.580
Authors: Satimai Aniwan; W Scott Harmsen; William J Tremaine; Sunanda V Kane; Edward V Loftus Journal: Mayo Clin Proc Date: 2018-07-04 Impact factor: 7.616
Authors: Remi Mahmoud; Shailja C Shah; Joren R Ten Hove; Joana Torres; Erik Mooiweer; Daniel Castaneda; Jason Glass; Jordan Elman; Akash Kumar; Jordan Axelrad; Thomas Ullman; Jean-Frederic Colombel; Bas Oldenburg; Steven H Itzkowitz Journal: Gastroenterology Date: 2018-12-07 Impact factor: 22.682